

**Table 7. NEUROINFLAMMATION AND CYTOKINE-TARGETED INTERVENTIONS : Targeting IL-7**

Target	Drug	Main Indications	CT Number , Title, Study Protocol	Neurological Implications
<p><b>IL-7</b></p>	<p><b>CYT-107</b> Recombinant Interleukin-7</p>	<p>-----</p>	<p><b>NCT04379076</b> InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort (ILIAD-7-UK) <b>Interventional Phase 2</b></p>	<p>IL-7 is effective in patients with <b>progressive multifocal leukoencephalopathy</b> caused by JC polyomavirus (Alstadhaug et al., 2014). May also exert proinflammatory activity (Ziegler et al., 1991) during spinal trauma (Bao et al., 2018), and promote the autoimmune aggression of the CNS in EAE mice (Lawson et al., 2015,Walline et al., 2011).</p>
			<p><b>NCT04407689</b> InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort (ILIAD-7-FR) <b>Interventional Phase 2</b></p>	
			<p><b>NCT04426201</b> InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (ILIAD-7-US-O) (ILIAD-7-US-O) <b>Interventional Phase 2</b></p>	
			<p><b>NCT04442178</b> InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (ILIAD-7-US-I) (ILIAD-7-US-I) <b>Interventional Phase 2</b></p>	